Abstract
Objective: To assess whether adjunct hematopoietic colony-stimulating factor (H-CSF) accelerates neutrophil recovery and improves survival. Design: A retrospective study. Setting: Medical/surgical intensive care unit (ICU). Patients: 30 neutropenic patients admitted to the ICU and treated with H-CSF. Controls were the preceding 30 neutropenic patients not treated with H-CSF. Measurements and results: Patient admission characteristics were reviewed. Endpoints were neutrophil recovery ( > 1.0 × 109/l), length of ICU stay and survival. Depth and duration of neutropenia (0.267 ± 0.04 × 109/l for 12 ± 1.7 days vs 0.293 ± 0.05 × 109/l for 15 ± 1.9 days; p = 0.67 and 0.21), and the Acute Physiology and Chronic Health Evaluation II and organ system failure scores were similar. Systemic candidiasis was lower in the H-CSF group (20 vs 3 %; p > 0.05). In 11 (36.6 %) and 10 (33.3 %) patients neutrophil count recovered ( > 1.0 × 109/l); H-CSF did not reduce the duration of neutropenia (7.8 ± 1.4 vs 5.7 ± 1.3 days; p = 0.28), the length of ICU stay (7.8 ± 1.1 vs 8.9 ± 1.5 days; p = 0.55) or improve survival (23 vs 10 %; p = 0.168). Conclusion: H-CSF for treatment of neutropenia in patients admitted to the ICU did not accelerate neutrophil recovery or improve survival.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 4 January 1999 Final revision received: 26 April 1999 Accepted: 26 May 1999
Rights and permissions
About this article
Cite this article
Bouchama, A., Khan, B., Djazmati, W. et al. Hematopoietic colony-stimulating factors for neutropenic patients in the ICU. Intensive Care Med 25, 1003–1005 (1999). https://doi.org/10.1007/s001340050996
Issue Date:
DOI: https://doi.org/10.1007/s001340050996